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It is well‑known that hypertension exacerbates chronic kidney disease (CKD) progression, however, 
the optimal target blood pressure (BP) level in patients with CKD remains unclear. This study aimed 
to assess the optimal BP level for preventing CKD progression. The risk of renal outcome among 
different BP categories at baseline as well as 1 year after, were evaluated using individual CKD patient 
data aged between 40 and 74 years from FROM‑J [Frontier of Renal Outcome Modifications in Japan] 
study. The renal outcome was defined as ≥ 40% reduction in estimated glomerular filtration rate 
to < 60 mL/min/1.73  m2, or a diagnosis of end stage renal disease. Regarding baseline BP, the group 
of systolic BP (SBP) 120–129 mmHg had the lowest risk of the renal outcome, which increased more 
than 60% in SBP ≥ 130 mmHg group. A significant increase in the renal outcome was found only in 
the group of diastolic BP ≥ 90 mmHg. The group of BP < 130/80 mmHg had a benefit for lowering the 
risk regardless of the presence of proteinuria, and it significantly reduced the risk in patients with 
proteinuria. Achieving SBP level < 130 mmHg after one year resulted in a 42% risk reduction in patients 
with SBP level ≥ 130 mmHg at baseline. Targeting SBP level < 130 mmHg would be associated with the 
preferable renal outcome.
Clinical Trial Registration‑URL: https:// www. umin. ac. jp/ ctr/. Unique identifier: UMIN000001159 
(16/05/2008).
Chronic kidney disease (CKD) is a worldwide health problem, which has a high global prevalence estimated 
between 11 and 13%, and also has similar prevalence among the Japanese  population1,2. Additionally, in many 
countries, as well as in Japan, the prevalence of CKD has continued to  rise3. CKD is an established risk factor for 
not only end stage renal disease (ESRD) but also cardiovascular disease (CVD) and all-cause  mortality4,5. Given 
these facts, prevention of CKD progression is one of the top public health priorities.
Hypertension is present in approximately 80 to 85% of patients with CKD, which is much higher compared to 
patients in the general  population6–9. In addition, blood pressure (BP) is strongly associated with kidney function 
and hypertension exacerbates CKD progression and incidence of ESRD, as well as the risk of  CVD10–13. Several 
OPEN
1Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School 
of Medicine, Dentistry, and Pharmaceutical Science, Okayama, Japan. 2Department of Chronic Kidney Disease and 
Cardiovascular Disease, Dentistry, and Pharmaceutical Science, Okayama University Graduate School of Medicine, 
Dentistry, and Pharmaceutical Science, Okayama, Japan. 3Department of Gastroenterological Surgery Transplant 
and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science, 
Okayama, Japan. 4University of Hyogo, Hyogo, Japan. 5Department of Nephrology, Faculty of Medicine, University 
of Tsukuba, Tsukuba, Ibaraki, Japan. 6Department of Human Resource Development of Dialysis Therapy for Kidney 
Disease, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama, 
Japan. 7Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and 
Dental Science, Niigata, Japan. 8Tokyo-Kita Medical Center, Kita-ward, Tokyo, Japan. 9Nagoya University, Nagoya, 
Aichi, Japan. 10Okayama University, Okayama, Japan. 11Yaizu City Hospital, Shizuoka, Japan. 12Department of 
Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical 
Science, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan. *email: hauchida@okayama-u.ac.jp
2
Vol:.(1234567890)
Scientific Reports |        (2021) 11:14990  | https://doi.org/10.1038/s41598-021-94467-z
www.nature.com/scientificreports/
clinical studies have shown that BP reduction decreased those risks, however, the optimal target level of BP in 
patients with CKD remains  unclear14–17. In fact, recent guidelines recommend to achieve lower BP goals, while 
the target BP level for patients with CKD varies depending on  guidelines18–20. The evaluation on the relevance 
of the new guidelines is necessary for appropriate management of patients with CKD.
The FROM-J [Frontier of Renal Outcome Modifications in Japan] study, which investigated the effect of 
lifestyle modification on the outcome of patients with CKD, is one of the most extensive prospective trials of 
patients with CKD in  Japan21. In the FROM-J study, all patients received treatment in accordance with the CKD 
clinical practice guideline of Japanese Society of Nephrology, which means that all enrolled patients were treated 
to maintain the same BP level. Patients in the group A (standard intervention) were only instructed to follow 
the  guideline22. On the other hand, patients in the group B (advanced intervention) received educational ses-
sions from dieticians and a letter regarding ideal lifestyle for CKD, as well as a notification one week before the 
 consultation21. In the FROM-J study, the association of BP levels and CKD progression has not been explored yet.
In the present study, we analyzed the relationship between patients’ BP levels and renal outcome. We aimed 
to examine the most preferable association of BP level and renal outcome in the patients with CKD.
Results
Baseline characteristics of study patients. Of the 2100 patients included in these analyses, 975 (46.4%) 
were categorized as CKD stage 1 or 2 and 1125 (53.6%) were CKD stage 3 to 5, the mean systolic BP (SBP) (± SD) 
was 137 ± 16 mmHg and that of diastolic BP (DBP) was 79 ± 11 mmHg, and the prevalence of hypertension 
was 90.8%. The baseline characteristics of patients are shown in Table 1 by SBP category and in Supplemental 
Table  S1 by DBP category. A total of 350 patients (16.7%) experienced the renal outcome during a median 
follow-up period of 5.1 years (interquartile range [IQR], 5.1–5.2 years).
The association of BP levels at baseline and the renal outcome. A strong association between 
baseline SBP levels and the renal outcome was identified. The SBP 120–129  mmHg group had the lowest 
risk of the renal outcome, which increased by more than  60% in the SBP 130–139 mmHg, 140–149 mmHg, 
150–159  mmHg and SBP ≥ 160  mmHg groups. (Fig.  1 and Table  2). The association between baseline DBP 
levels and the renal outcome was weaker than that of SBP. The significant increase was only observed in the 
DBP ≥ 90 mmHg group compared with the DBP 70–79 mmHg group (Fig. 1 and Table 2). The increased risk of 
the renal outcome at higher SBP levels was even greater in patients with an estimated glomerular filtration rate 
(eGFR) < 60 ml/min/1.73  m2. The SBP 120–129 mmHg group had the lowest risk, which increased more than 
two folds in the SBP ≥ 130 mmHg groups. (see Supplemental Figure S1  and Supplemental Table S2).
To examine the combined effects of various levels of SBP and DBP on the renal outcome, we classified 
baseline BP levels into nine groups, in which SBP was classified into three; < 130 mmHg, 130–149 mmHg 
and ≥ 150 mmHg, and DBP was into three; < 70 mmHg, 70–89 mmHg and ≥ 90 mmHg. We then calculated the 
risk ratios of the renal outcome for each group. The BP < 130/70–89 mmHg group had the lowest frequency of the 
renal outcome, then it was used as a reference to calculate the risk ratios. No significant increase was observed 
in the BP < 130/ < 70 mmHg and < 130/ ≥ 90 mmHg groups. On the contrary, those with an SBP ≥ 130 mmHg 
had a significantly increased risk. When the DBP levels were the same, the risk ratios increased as the SBP level 
increased, while the risk ratios did not increase as the DBP level raised when the SBP levels were same (Table 2). 
The risk ratio results consisted of six SBP groups and four DBP groups is shown in Supplemental Table S2.
For estimating varying impact of managing BP on the renal outcome due to the presence of proteinuria, 
the difference in the renal outcome between the two baseline BP levels, which were BP < 130/80 mmHg and 
SBP ≥ 130 mmHg and/or DBP ≥ 80 mmHg, was compared in patients with and without proteinuria, respec-
tively. Proteinuria was defined as baseline proteinuria ± or more by dipstick test. Two patients were excluded in 
this subgroup analysis because of the lack of proteinuria measurement at baseline. The association of baseline 
BP levels with renal outcome differed according to the presence of baseline proteinuria levels (Fig. 1). Among 
patients with proteinuria, the baseline BP < 130/80 mmHg group significantly reduced the risk of the renal out-
come. We also found that the risk of renal outcome tended to reduce in those with a baseline BP < 130/80 mmHg 
among patients without proteinuria, although the difference between the two baseline BP levels did not reach 
the statistical significance.
The association BP levels after 1 year with renal outcome. We investigated the association between 
the renal outcome and BP levels at baseline and 1 year later. A total of 56 patients were excluded because of miss-
ing measurement of the BP level of 1 year later or the renal outcome reached within 12 months. The achiever was 
defined as patients who attained the target SBP or DBP levels at both baseline and after 1 year: the late failure 
as patients who attained the target SBP or DBP at baseline but not after 1 year: the late achiever as patients who 
did not attain the target SBP or DBP at baseline but achieved after 1 year: and the failure as patients who did not 
attain the target SBP or DBP both at baseline and after one year.
A significant association between SBP change and the risk of renal outcome was found. The failure signifi-
cantly increased the risk of renal outcome by more than 3.1 times in comparison with the achiever (Fig. 2 and 
Table 3). The difference between the late failure and the achiever increased over the follow-up period, and the 
late failure reached an increase of more than 80% over the achiever. The late achiever also resulted in a significant 
increase compared to the achiever, however, it reduced the risk by 42% compared to the failure (HR, 0.58; 95% 
CI, 0.41–0.80). No significant difference in renal outcome risk was observed in the DBP management.
A subgroup analysis of 541 patients with severe CKD with eGFR < 45 ml/min/1.73  m2 also demonstrated 
these trends (Supplemental Figure S2 and Supplemental Table S3). This analysis showed that the late achiever 
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provided a  63% reduction in the risk of renal outcomes compared with the failure. (HR of the late achiever 
versus the failure, 0.37; 95% CI, 0.21–0.60).
Comparison of the Group A with B. Furthermore, we compared the group A and B in accordance with 
their BP levels on renal outcome in patients with baseline eGFR < 60 ml/min/1.73  m2 (n = 1125) and those with 
baseline eGFR ≥ 60  ml/min/1.73  m2 (n = 975), respectively. Analysis of patients with eGFR < 60  ml/min/1.73 
 m2 showed that the group B had a significant reduction in patients with a baseline SBP ≥ 130 mmHg and/or 
DBP ≥ 80  mmHg, despite no significant difference in those with baseline BP < 130/80  mmHg. We found no 
difference of renal outcome between the group A and B in patients with eGFR ≥ 60 ml/min/1.73  m2 (Fig. 3). 
The proportion of patients with a BP level < 130/80 mmHg after 1 year did not differ between group A (20.7%) 
and B (22.6%) among patients with eGFR < 60  ml/min/1.73  m2 whose baseline SBP ≥ 130  mmHg and/or 
DBP ≥ 80 mmHg (P = 0.51 by Chi-squared test).
Table 1.  Baseline characteristics of patients stratified by SBP categories. Unless otherwise specified, data are 
presented as the mean ± SD. SBP systolic blood pressure, BMI body mass index, CKD chronic kidney disease, 
DBP diastolic blood pressure, RAS-I renin angiotensin system inhibitor, IQR interquartile range, BUN blood 
urea nitrogen, eGFR estimated glomerular filtration rate, HbA1c hemoglobin A1c, TC total cholesterol, HDL-C 

















Male sex, % 71.4 72.9 74.3 69.5 69.7 73.5 71.2
Age, year 62.5 ± 8.3 62.4 ± 8.7 61.9 ± 8.8 62.7 ± 8.2 62.3 ± 8.0 62.9 ± 7.7 63.0 ± 8.4
BMI, kg/m2 25.7 ± 3.8 25.4 ± 3.7 25.6 ± 3.8 25.5 ± 3.7 25.8 ± 4.0 26.1 ± 3.7 25.8 ± 4.1
Abdominal 
girth, cm 90.0 ± 9.9 87.4 ± 10.7 89.0 ± 9.8 90.2 ± 9.7 91.2 ± 9.8 90.6 ± 9.1 91.1 ± 10.4
Current smok-
ing, % 22.5 19.4 24.5 21.7 22.5 24.2 23.0
Diabetes mel-
litus, % 61.1 58.1 58.5 59.0 61.0 68.4 67.0
Hyperten-
sion, % 90.8 77.7 87.5 91.0 95.1 96.1 95.8
Dyslipidemia, 
% 69.3 66.8 69.5 69.3 71.2 72.3 63.4
Hyperurice-
mia, % 38.8 39.3 40.3 40.4 35.6 35.2 42.4
Medication
Anti-hyperten-
sive, % 86.1 73,8 81.8 85.9 89.4 93.3 93.2
Use of RAS-I, % 72.8 65.1 70.9 70.5 74.6 79.8 79.6
Laboratory values
Positive pro-

















g/dL 7.2 ± 0.5 7.2 ± 0.5 7.2 ± 0.5 7.3 ± 0.5 7.3 ± 0.5 7.1 ± 0.5 7.2 ± 0.5
Albumin, g/dL 4.3 ± 0.4 4.2 ± 0.3 4.3 ± 0.3 4.3 ± 0.4 4.3 ± 0.4 4.2 ± 0.4 4.2 ± 0.4
Hemoglobin, 
g/dL 13.8 ± 1.8 13.6 ± 1.8 13.9 ± 1.8 13.8 ± 1.8 13.9 ± 1.7 13.8 ± 1.9 13.6 ± 2.1
BUN, mg/dL 19.6 ± 8.0 20.2 ± 8.0 18.9 ± 7.2 19.5 ± 8.0 19.4 ± 8.1 19.5 ± 8.4 20.7 ± 8.7
Creatinine, 
mg/dL 1.07 ± 0.49 1.10 ± 0.44 1.05 ± 0.48 1.07 ± 0.48 1.05 ± 0.49 1.10 ± 0.57 1.16 ± 0.53
eGFR, ml/
min/1.73  m2 59.1 ± 21.9 57.0 ± 21.2 60.3 ± 21.1 59.0 ± 22.1 60.8 ± 22.2 59.1 ± 21.7 55.7 ± 22.7
HbA1c, % 6.2 ± 1.2 6.0 ± 1.1 6.1 ± 1.2 6.1 ± 1.1 6.2 ± 1.3 6.3 ± 1.2 6.3 ± 1.1
Uric acid, mg/
dL 6.2 ± 1.2 6.2 ± 1.8 6.2 ± 1.5 6.1 ± 1.5 6.1 ± 1.6 6.0 ± 1.5 6.5 ± 1.8
TC, mg/dL 198 ± 35 193 ± 34 195 ± 34 197 ± 37 201 ± 37 195 ± 357 203 ± 33
HDL-C, mg/dL 54 ± 16 55 ± 16 53 ± 15 54 ± 15 56 ± 17 53 ± 14 54 ± 18
Non-HDL-C, 
mg/dL 147 ± 37 139 ± 34 145 ± 36 147 ± 37 149 ± 39 145 ± 36 153 ± 39
Triglyceride, 
mg/dL 173 ± 140 151 ± 98 170 ± 131 172 ± 118 176 ± 171 176 ± 136 202 ± 176
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Discussion
In the present study, we found that baseline SBP level of ≥ 130 mmHg and DBP level of ≥ 90 mmHg was associated 
with the increase of the risk of the renal outcome in patients with CKD. The association of baseline BP levels with 
the renal outcome varied by baseline proteinuria level. Among patients with proteinuria, the higher baseline BP 
levels significantly increased the risk of the renal outcome. Second, the renal outcome was also strongly associated 
with the SBP level after one year. In fact, the late achiever had a 42% reduction of the risk compared to the failure. 
Third, among the patients with eGFR < 60 ml/min/1.73  m2 who did not meet the BP level of < 130/80 mmHg at 
baseline, the group B showed a significant association of lowering risk in renal outcome compared to the group A.
A few observational studies have shown that SBP level was independently associated with the presence of CKD 
and patients with baseline SBP level of ≥ 130 mmHg had increased risk of CKD  progression11,12,23–28. Our analyses 
using baseline BP levels demonstrated that SBP level of ≥ 130 mmHg results in a significant association with 
increment of risk of the renal outcome: more than 60% increase in the risk among patients with all CKD stages. 
Moreover, the risk more than doubled in patients with eGFR < 60 ml/min/1.73  m2. The SBP 120–129 mmHg 
group had a lower risk of the renal outcome than the SBP < 120 mmHg group, although there was no significant 
difference. Thus, it is likely concluded that the optimal SBP level for better renal outcome in patients with CKD 
could be < 130 mmHg, rather than < 120 mmHg. Regarding DBP, as prior studies have shown, baseline DBP 
Figure 1.  Kaplan–Meier analyses for renal outcome based on baseline SBP and DBP levels (A,B), and stratified 
by the presence or absence of baseline proteinuria (C,D). (A) Analyses of baseline SBP levels (6 groups); The 
SBP 120–129 mmHg group had the lowest risk of the renal outcome. (B) Analyses of baseline DBP levels (4 
groups); the risk of renal outcome significantly increased only in the DBP ≥ 90 mmHg group compared to the 
DBP 70–79 mmHg group. *p < 0.05 vs SBP 120–129 mmHg (Log-rank), **p < 0.001 vs SBP 120–129 mmHg 
(Log-rank), †p < 0.05 vs DBP 70–79 mmHg (Log-rank). (C) Patients with proteinuria; proteinuria was defined 
as ≥  ± by dipstick test. The baseline BP < 130/80 mmHg group significantly reduced the risk of the renal outcome 
compared to the other. (D) Patients without proteinuria; No significant difference was found in renal outcome. 
SBP systolic blood pressure, DBP diastolic blood pressure, BP blood pressure, HR hazard ratio. Hazard ratios 
have been adjusted for nine prespecified baseline factors (age, sex, body mass index, smoking, presence of 
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levels had less association with the renal outcome than baseline SBP  levels23,29. The significantly increased risk 
of the renal outcome in the DBP ≥ 90 mmHg group suggests that DBP level < 90 mmHg may be better on renal 
outcome. Given the minor difference between the DBP 70–79 mmHg and 80–89 mmHg groups at baseline and 
among the groups categorized by DBP levels after one year, it is difficult to conclude that DBP level should be 
controlled at < 80 mmHg. Since decreased DBP level sometimes results from stiffening of the aorta, which is 
one of the risks of CKD progression, the benefits of DBP levels at < 80 mmHg may be obscured in patients with 
severe arterial  stiffness30.
Higher degrees of urinary protein excretion are also associated with a more rapid progression of  CKD31,32. 
In addition, the risk of CKD progression at higher BP levels is greater in the patients with  proteinuria31–33. In 
previous studies, lowering BP level reduced the risk of CKD progression among patients with a high degree of 
proteinuria, despite the lack of a significant reduction among patients with small degree of proteinuria 16,17,34. 
Table 2.  Risk of renal outcomes based on baseline SBP and DBP levels. Hazard ratios have been adjusted for 
nine prespecified baseline factors (age, sex, body mass index, smoking, presence of diabetes mellitus, presence 
of dyslipidemia, presence of hyperuricemia, use of anti-hypertensive medication and intervention arm). SBP 
systolic blood pressure, DBP diastolic blood pressure, HR hazard ratio, CI confidence interval.
(A) Baseline SBP
Baseline SBP Events, % Adjusted HR (95% CI) P value
 < 120 10.5 1.29 (0.75–2.18) 0.345
120–129 9.5 1 [reference]
130–139 13.7 1.60 (1.08–2.41) 0.018
140–149 16.0 1.77 (1.18–2.71) 0.005
150–159 22.9 2.73 (1.77–4.26)  < 0.001
 ≥ 160 26.2 2.88 (1.86–4.52)  < 0.001
(B) Baseline DBP
Baseline DBP Events, % Adjusted HR (95% CI) P value
 < 70 15.1 1.01 (0.70–1.44) 0.961
70–79 13.9 1 [reference]
80–89 14.2 1.08 (0.81–1.44) 0.588
 ≥ 90 20.6 1.72 (1.24–2.37) 0.001
(C) Risk ratios of renal outcomes based on baseline BP levels
Risk ratio (95% CI) DBP < 70 70 ≤ DBP < 90 DBP ≥ 90
SBP < 130 1.28 (0.77–2.12) 1 [reference] 1.39 (0.46–4.19)
130 ≤ SBP < 150 2.29 (1.38–3.81) 1.51 (1.06–2.16) 1.85 (1.16–2.95)
SBP ≥ 150 2.30 (1.06–5.00) 2.68 (1.82–3.95) 2.79 (1.87–4.16)
Figure 2.  Kaplan–Meier analyses of renal outcome based on management of BP levels after 1 year (n = 2044). 
Patients were divided into 4 groups according to management of SBP and DBP levels, respectively, at baseline 
and after 1 year. (A) Analyses of SBP level at baseline and after 1 year; the failure and the late achiever had 
significant higher risk of renal outcome compared to the achiever. (B) Analyses of DBP level at baseline and 
after 1 year; no significant difference was found among groups. *p < 0.05 vs achiever (Log-rank), **p < 0.001 vs 
achiever (Log-rank). BP blood pressure.
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In the present study, among patients with proteinuria, those with BP level of < 130/80 mmHg was significantly 
associated with risk reduction. However, among the patients without proteinuria, the risk reduction of those with 
a BP of < 130/80 mmHg did not reach significant difference but the tendency of decreased risk was found. These 
results suggest possible benefits for patients with CKD by controlling their BP at < 130/80 mmHg, regardless of 
presence or absence of proteinuria.
Varying target levels have been used for patients undergoing intensive BP control group and the results have 
been  inconsistent14–17,35–38. The MDRD (the Modification of Diet in Renal Disease) and AASK (the African 
American Study of Kidney Disease and Hypertension) trials targeted mean arterial pressure to ≤ 92 mmHg 
(equivalent to approximately 125/75 mmHg)36,37. Both trials showed no significant benefit of intensive BP con-
trol on CKD progression, whereas, with extended follow-up, intensive BP control showed significant reduction 
of CKD progression in patients with elevated level of proteinuria. The SPRINT (the Systolic BP Intervention 
Trial) and ACCORD BP (Action to Control Cardiovascular Risk in Diabetes BP) trials targeted SBP to < 120 
 mmHg15,35. In these trials, no significant difference was observed between randomized groups in ≥ 50% decline 
in eGFR or ESRD. A few studies showed that intensive BP lowering had adverse effects on CKD  progression14,35. 
Distinct from previous intervention trials, in the present study, all enrolled patients had the same BP target 
level of < 130/80 mmHg. The analyses on the management of SBP levels after one year suggests that achieving 
the target SBP level after one year could significantly retards CKD progression among patients with SBP level 
of ≥ 130 mmHg at baseline. In addition, the analyses imply the possibility that failing to meet the target SBP level 
after one year would exacerbate CKD progression even though it was achieved at baseline. In fact, the difference 
in the risk between the late failure and the achiever increased over the follow-up period, and the former had 80% 
increased risk compared to the latter. A post hoc analysis of SPRINT showed an increase in acute kidney injury 
events in the intensive treatment arm among the patients with eGFR < 45 ml/min/1.73  m2 39. However, in the 
present subgroup analysis of patients with eGFR < 45 ml/min/1.73  m2, the late achiever was also associated with 
reduction of the risk of renal outcome compared to the failure. Moreover, the association of the reduction was 
even stronger than the analysis which included patients with eGFR ≥ 45 ml/min/1.73  m2. This fact may suggest 
that targeting a slightly moderate SBP level to < 130 mmHg, rather than to < 120 mmHg, would minimize adverse 
effects and maximize benefit for the renal outcome.
In the FROM-J study, BP levels during the study period and the anti-hypertensive medication were almost 
identical between the  groups21. On the contrary, the average body mass index and hemoglobin A1c were signifi-
cantly lower after one year in the group B compared to the group A. A significantly lower rate of absence from 
regular clinical visits and higher co-treatment rate with nephrologists were observed in the group  B21. In the 
current study, the group B demonstrated a significantly reduced risk of renal outcome among the patients with 
baseline eGFR < 60 ml/min/1.73  m2 who did not meet the BP level of < 130/80 mmHg at baseline. The lack of a 
significant difference in BP levels between the group A and B suggests that treatment of comorbidities, such as 
diabetes and obesity, as well as lifestyle modifications, may have further benefits to improve renal prognosis in 
patients with reduced kidney function who do not achieve the target BP level.
Our analysis has several limitations. First, since this was a post hoc analysis of the FROM-J study, unknown 
risk factors, which may have affected the results, were not completely excluded. Second, patients aged ≥ 75 years 
were excluded from the present study; therefore, our findings are unable to be applied to patients aged ≥ 75 years. 
Third, the assessment for the potential adverse effects associated with SBP level of < 110 mmHg or DBP level 
of < 60 mmHg was not performed, due to the lack of the applicable patient’s number. Fourth, we lacked data 
on some potentially important unmeasured confounders such as duration of hypertension or BP levels before 
Table 3.  Risk of renal outcomes based on management of blood pressure levels after one year (n = 2044). 
Hazard ratios have been adjusted for nine prespecified baseline factors (age, sex, body mass index, smoking, 
presence of diabetes mellitus, presence of dyslipidemia, presence of hyperuricemia, use of anti-hypertensive 
medication and intervention arm). SBP systolic blood pressure, DBP diastolic blood pressure, HR hazard ratio, 
CI confidence interval.
(A) SBP at baseline and after 1 year
Group
SBP
Adjusted HR (95% CI) P valueBaseline After 1 year
Achiever  < 130  < 130 1 [reference]
Late achiever  ≥ 130  < 130 1.80 (1.07–3.11) 0.027
Late failure  < 130  ≥ 130 1.81 (1.04–3.22) 0.036
Failure  ≥ 130  ≥ 130 3.11 (2.02–5.05)  < 0.001
(B) DBP at baseline and after 1 year
Group
DBP
Adjusted HR (95% CI) P valueBaseline After 1 year
Achiever  < 80  < 80 1 [reference]
Late achiever  ≥ 80  < 80 1.07 (0.77–1.49) 0.669
Late failure  < 80  ≥ 80 0.91 (0.56–1.41) 0.681
Failure  ≥ 80  ≥ 80 1.32 (0.98–1.78) 0.068
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recruitment into the study. Fifth, the presence of proteinuria was based on the results of dip-stick test, which 
has the possibility of a false negative or false positive. However, dip stick test is simpler and less expensive and 
more commonly used than the quantitative test. It is therefore convenient for non-specialists and general prac-
titioners (GPs).
In conclusion, the significant association of the SBP ≥ 130 mmHg and DBP ≥ 90 mmHg groups at baseline 
with the renal outcome was found. Taking the result of BP levels at baseline and after one year together, targeting 
the SBP level to < 130 mmHg would be preferable for preventing CKD progression. The current guidelines which 
recommend a target BP level of < 130/80 mmHg for CKD patients appears to be appropriate.
Methods
Design. The FROM-J study was a prospective cluster-randomized trial, and enrolled patients with CKD who 
were under consultation with GPs. Details of the study design have previously been  published21,40. The study was 
a Central Institutional Review Board Program; the Committee on Ethics in Strategic Research of the Kidney 
Foundation, Japan, and the institutional review board at the University of Tsukuba examined and approved the 
implementation plans and their  revision21,40. In brief, the local medical associations were randomly assigned to 
two intervention groups. All patients received treatment in accordance with the CKD clinical practice guideline 
of Japanese Society of Nephrology, and patients in the group A (standard intervention) were only instructed 
to follow the  guideline22. On the other hand, patients in the group B (advanced intervention) received three 
additional interventions. Firstly, the group B patients received 30-min educational sessions from dieticians upon 
Figure 3.  Kaplan–Meier analyses of renal outcome between the group A and B, stratified by baseline BP levels 
in patients with eGFR < 60 ml/min/1.73  m2 (A,B) and ≥ 60 ml/min/1.73  m2 (C,D). The difference in the effect 
on renal outcome between the group A and B was compared in the patients with eGFR < 60 ml/min/1.73  m2 
(A,B). Patients in group A (standard intervention) were simply instructed to follow the medical guidelines of 
the Japanese Society of Nephrology. On the other hand, patients in group B (advanced intervention) received an 
educational session by a dietitian and a letter regarding ideal lifestyle for CKD and were notified 1 week prior to 
the consultation. (A) Baseline SBP < 130 mmHg and DBP < 80 mmHg; No significant difference was observed. 
(B) The group B significantly reduced renal outcome compared to the group A. No significant difference was 
observed in patients with eGFR ≥ 60 ml/min/1.73  m2 (C,D). BP blood pressure, SBP systolic blood pressure, 
DBP diastolic blood pressure, eGFR estimated glomerular filtration rate.
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visiting their local GP offices every 3 months. Secondly, the group B patients received a CKD treatment report 
from the coordinating center bimonthly to learn about CKD and their ideal lifestyle to prevent progression. In 
addition, they received a notification 1 week before the consultation in order to prevent their withdrawal from 
treatment. Thirdly, the group B GPs received comments about their patients’ data, focusing on the gap between 
target and practice, from the coordinating center.
Patients’ BP level was measured by physicians or certified staff with the arm-cuff position at the heart 
level during rest in a seated position. The measurement was performed two times at intervals of 1–2 min by 
the auscultation method or by using an automatic  sphygmomanometer41. In both groups, the BP target level 
of < 130/80 mmHg was applied for patients with all CKD stages, and that of < 125/75 mmHg was applied for 
patients with proteinuria > 1.0 g/day. The study was conducted in accordance with Ethical Guidelines for Clinical 
Studies (revised on December 28, 2004, of the Ministry of Health, Labor, and Welfare) and the Ethical Guidelines 
for Epidemiological Studies (revised on August 16, 2007, of the Ministries of Education, Culture, Sports, Science, 
and Technology/ Health, Labor, and Welfare).
Patients. In FROM-J study, a total of 2379 patients aged 40 to 74 were enrolled. Eligible participants were 
those who had Stage 1, 2, 4 or 5 CKD, or Stage 3 CKD with proteinuria (ratio of urinary protein/urinary creati-
nine ≥ 0.3 g/gCr, or proteinuria ≥ 1 +) and diabetes or Stage 3 CKD with proteinuria (ratio of urinary protein/
urinary creatinine > 0.3 g/gCr or proteinuria > 1 +) and hypertension, who were under consultation with GPs. 
Dialysis patients, renal transplant patients, and those who did not consent were excluded from the study. Partici-
pant recruitment was from April 1, 2008 to October 19, 2008. On October 20, 2008, the local medical associa-
tions were randomly assigned at a ratio of 1:1 to group A or group B. Randomization was performed centrally 
by means of a com- puter-generated random-number sequence. The primary intervention study and follow-up 
duration lasted from October 20, 2008, to March 31, 2012. For our analyses, 104 patients who chose to withdraw, 
74 patients without BP or eGFR data at baseline, 23 patients who had only one measurement of BP in the first 
6 months, and 78 patients who had only one measurement of eGFR during the study period, were excluded, 
resulting in the final number of participants of 2100 (Fig. 4). All patients provided written informed consent.
Outcomes. We focused on evaluating the association of BP levels with renal outcome. Given that a 40% 
reduction in eGFR is strongly associated with the risk of ESRD and examined as an endpoint in recent large 
clinical  trials42,43, we defined renal outcome as eGFR reduction from baseline of ≥ 40% or a diagnosis of ESRD. 
Patients with a 40% reduction in eGFR who preserved 60 mL/min/1.73  m2 and more were not considered to 
have reached the endpoint. ESRD was defined by the initiation of dialysis or receipt of a kidney transplant.
First, we categorized baseline SBP levels into six groups: SBP < 120 mmHg, 120–129 mmHg, 130–139 mmHg, 
140–149 mmHg, 150–159 mmHg, and ≥ 160 mmHg, and also categorized baseline DBP levels into four groups: 
DBP < 70 mmHg, 70–79 mmHg, 80–89 mmHg, and ≥ 90 mmHg. The relationship between the groups and 
the renal outcome were statistically analyzed. Subgroup analysis was performed based on the presence of 
proteinuria (the definition of proteinuria as ≥  ± by dipstick test) to assess the benefit of low BP level, which 
was < 130/80 mmHg at baseline, on renal outcome.
Second, we investigated the association of BP at baseline and after 1 year with the renal outcome. In patients 
without measurement of BP just 12 months later, the BP of the 2 months before and after was taken as the BP of 1 
Number of enrolled patients (n=2100)
2379 patients with CKD from FROM-J study
withdrew (n=104)
BP measurements only once
in the first 6 months (n=23)
eGFR measurements only once 
during the study period (n=78)
lack of baseline blood pressure or eGFR data (n=74)
Figure 4.  Flow chart of patients. CKD chronic kidney disease, FROM-J Frontier of Renal Outcome 
Modifications in Japan, eGFR estimated glomerular filtration rate.
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year later. With a target SBP level of < 130 mmHg and a target DBP level of < 80 mmHg, patients were divided into 
four groups based on the achievement of the target SBP and DBP levels at baseline and after 1 year, respectively. 
We intended to confirm whether achievement of the target BP level after 1 year was associated with reduction 
of the risk of the renal outcome.
Furthermore, we compared the group A with B to assess the benefit of lifestyle modification in terms of 
preventing CKD progression. We examined the difference between the two groups stratified by baseline eGFR 
and BP levels. eGFRs in this study were calculated using the following  formula44:
Statistical analysis. Cumulative probability of the renal outcome was traced using the Kaplan–Meier 
curves and analyzed using a log-rank test. The effects of BP levels on the renal outcome were evaluated using 
Cox proportional hazards regression models with adjustment for age, sex, body mass index, current smoking, 
presence of diabetes mellitus, presence of dyslipidemia, intervention arm, presence of hyperuricemia and use of 
anti-hypertensive medication. We calculated the risk ratios of renal outcome for each stratified baseline BP level. 
A two-tailed value of P < 0.05 was defined as the statistically significant. All analyses were performed using JMP, 
version 15 (SAS Institute Inc., Cary, NC, USA).
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